



HIV

MK-8527 MSD

lenacapavir Gilead

islatravir MSD

cabotegravir
4-monthly ViiV

doravirine MSD

GS-1720 Gilead

GS-4182 Gilead

Monoclonal antibodies for
HIV post-natal prophylaxis

Multiple innovators

TAF/EVG insert Conrad

ulonivirine MSD

VH4524184 ViiV

VH4011499 ViiV



TUBERCULOSIS

quabodepistat Otsuka

alpipectir GSK

bedaquiline
long-acting Janssen

delpazolid LegoChem
BioSciences

ganfeborole GSK

macozinone EPFL

sudapyridine Shanghai
Jiatan Biotech



VIRAL HEPATITIS

HEPATITIS C

bemnifosbuvir Atea

ruzasvir Atea

HEPATITIS B

bepirovirsen GSK



RESPIRATORY
SYNCYTIAL VIRUS

nirsevimab AstraZeneca/
Sanofi

clesrovimab MSD



MALARIA

MicroCoat AS/AQ
FluidPharma



PANDEMIC &
EPIDEMIC THREATS

SEASONAL INFLUENZA

baloxavir
marboxil Roche



CYSTIC FIBROSIS

elexacaftor/ivacaftor/tezacaftor

Vertex



ONCOLOGY

MULTIPLE CANCER INDICATIONS

Immune checkpoint
inhibitors

including Multiple innovators
pembrolizumab MSD

LUNG CANCER

aumolertinib Hansoh
Pharma

osimertinib Astrazeneca

adagrasib Bristol Myers Squibb

lazertinib Janssen

sotorasib Amgen

BREAST CANCER

abemaciclib Eli Lilly

ribociclib Novartis

trastuzumab SQ Roche

CHRONIC LYMPHOCYTIC LEUKAEMIA

zanubrutinib Beigene

PROSTATE CANCER

apalutamide Janssen

darolutamide Bayer

LOW-GRADE GLIOMAS

dabrafenib/trametinib

Novartis



DIABETES,
CARDIOVASCULAR
& METABOLIC
DISORDERS

Incretin-based therapies
(incl. GLP1 RA)

Multiple innovators

including

orforglipron Eli Lilly

semaglutide Novo Nordisk

tirzepatide Eli Lilly

retatrutide Eli Lilly

Insulin analogues

Multiple innovators

cardiovascular fixed-dose
combination therapies

Multiple innovators

PRIORITY LIST

WATCHLIST

November 2025